Glaukos (GKOS) Competitors

Glaukos (NYSE:GKOS) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

Does the media favor GKOS or ZBH?

In the previous week, Glaukos had 9 more articles in the media than Zimmer Biomet. MarketBeat recorded 20 mentions for Glaukos and 11 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.07 beat Glaukos' score of 0.81 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	5 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is GKOS or ZBH more profitable?

Zimmer Biomet has a net margin of 11.86% compared to Glaukos' net margin of -21.43%. Zimmer Biomet's return on equity of 12.73% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-21.43%	-8.59%	-6.61%
Zimmer Biomet	11.86%	12.73%	7.34%

Which has more risk and volatility, GKOS or ZBH?

Glaukos has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Which has better valuation and earnings, GKOS or ZBH?

Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$432.95M	11.40	-$146.37M	-$1.65	-52.36
Zimmer Biomet	$7.68B	2.34	$903.70M	$4.52	20.05

Do institutionals & insiders have more ownership in GKOS or ZBH?

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 5.8% of Glaukos shares are owned by company insiders. Comparatively, 1.4% of Zimmer Biomet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Do analysts prefer GKOS or ZBH?

Glaukos currently has a consensus price target of $127.42, indicating a potential upside of 47.49%. Zimmer Biomet has a consensus price target of $111.39, indicating a potential upside of 22.91%. Given Glaukos' stronger consensus rating and higher possible upside, equities research analysts clearly believe Glaukos is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Zimmer Biomet	2 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.35

Summary

Glaukos beats Zimmer Biomet on 9 of the 17 factors compared between the two stocks.